Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of breast cancer
3.2.1.2 Advancements in genomic technologies
3.2.1.3 Rising expenditure for cancer treatment
3.2.1.4 Growing adoption of personalized medicine and precision therapy
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of PARP inhibitor biomarker test kits and assays
3.2.2.2 Limited awareness and understanding of PARP inhibitors biomarkers
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Kits
5.3 Assays
Chapter 6 Market Estimates and Forecast, By Service, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 BRCA (Breast cancer gene) 1 & 2 testing
6.3 HRD (Homologous recombination deficiency) testing
6.4 HRR (Homologous recombination repair) testing
6.5 Other services
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Breast cancer
7.3 Ovarian cancer
7.4 Other applications
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals and clinics
8.3 Diagnostic laboratories
8.4 Academic and research institutes
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Agilent Technologies, Inc.
10.2 Ambry Genetics
10.3 Amoy Diagnostics Co., Ltd.
10.4 Centogene N.V
10.5 Illumina, Inc.
10.6 Invitae Corporation
10.7 Myriad Genetics, Inc.
10.8 Neogenomics, Inc.
10.9 QIAGEN N.V.
10.10 Thermo Fisher Scientific Inc.
